Cargando…

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification

The inhibition of FMS-like tyrosine kinase 3 (FLT3) activity using small-molecule inhibitors has emerged as a target-based alternative to traditional chemotherapy for the treatment of acute myeloid leukemia (AML). In this study, we report the use of structure-based virtual screening (SBVS), a comput...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ke, Yi-Yu, Singh, Vivek Kumar, Coumar, Mohane Selvaraj, Hsu, Yung Chang, Wang, Wen-Chieh, Song, Jen-Shin, Chen, Chun-Hwa, Lin, Wen-Hsing, Wu, Szu-Huei, Hsu, John T. A., Shih, Chuan, Hsieh, Hsing-Pang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483777/ https://www.ncbi.nlm.nih.gov/pubmed/26118648 http://dx.doi.org/10.1038/srep11702

Ejemplares similares

Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design
por: Chandar Charles, M. Ramya, et al.
Publicado: (2021)

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
por: Hasegawa, Hiroko, et al.
Publicado: (2020)

FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
por: Ramos, Maria I, et al.
Publicado: (2013)

FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others
por: de Arruda, Vanessa Y.N., et al.
Publicado: (2017)

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)

Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer
por: Syed, Safiulla Basha, et al.
Publicado: (2017)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells
por: Kawase, Tatsuya, et al.
Publicado: (2019)

Reversible Testicular Toxicity of Piperine on Male Albino Rats
por: Chinta, Gopichand, et al.
Publicado: (2017)

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
por: Perrone, Salvatore, et al.
Publicado: (2023)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
por: Kim, Shin-Young, et al.
Publicado: (2008)

Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses
por: Pais, Roshan, et al.
Publicado: (2019)

Serum Soluble Fms-Like Tyrosine Kinase 1 (sFlt-1) Predicts the Severity of Acute Pancreatitis
por: Dumnicka, Paulina, et al.
Publicado: (2016)

BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells
por: Cheung, Chun Hei Antonio, et al.
Publicado: (2011)

The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy
por: Kuncman, Łukasz, et al.
Publicado: (2022)

Pseudogene fms-related tyrosine kinase 1 pseudogene 1 (FLT1P1) cooperates with RNA binding protein dyskeratosis congenita 1 (DKC1) to restrain trophoblast cell proliferation and angiogenesis by targeting fms-related tyrosine kinase 1 (FLT1) in preeclampsia
por: Chi, Zhenjing, et al.
Publicado: (2021)

Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers
por: Cheung, Chun Hei Antonio, et al.
Publicado: (2009)

Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice
por: Della Verde, Giacomo, et al.
Publicado: (2021)

High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: a prospective pilot study from India
por: Sharawat, Surender Kumar, et al.
Publicado: (2016)

FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics
por: Rezaei, Narges, et al.
Publicado: (2017)

ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application
por: Lee, Sungyoung, et al.
Publicado: (2023)

Structural Elucidation of the DFG-Asp in and DFG-Asp out States of TAM Kinases and Insight into the Selectivity of Their Inhibitors
por: Messoussi, Abdellah, et al.
Publicado: (2014)

Computational Study of the “DFG-Flip” Conformational Transition in c-Abl and c-Src Tyrosine Kinases
por: Meng, Yilin, et al.
Publicado: (2014)

Proceedings of a CNRS-DFG Symposium
por: Wagner, Siegfried
Publicado: (1995)

FMS-like tyrosine kinase 3 is required for dendritic cell development in peripheral lymphoid tissues
por: Waskow, Claudia, et al.
Publicado: (2008)

Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia
por: Pazhakh, Vahid, et al.
Publicado: (2011)

Fms-Like Tyrosine Kinase 3 Ligand Controls Formation of Regulatory T Cells in Autoimmune Arthritis
por: Svensson, Mattias N. D., et al.
Publicado: (2013)

FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma
por: Zhu, Zuoquan, et al.
Publicado: (2021)

Serum Concentrations of Angiopoietin-2 and Soluble fms-Like Tyrosine Kinase 1 (sFlt-1) Are Associated with Coagulopathy among Patients with Acute Pancreatitis
por: Dumnicka, Paulina, et al.
Publicado: (2017)

Rational design and synthesis of 2-(1H-indazol-6-yl)-1H-benzo[d]imidazole derivatives as inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants
por: Im, Daseul, et al.
Publicado: (2022)

PB1834: CLEVO: A NON-INTERVENTIONAL STUDY TO INVESTIGATE CLONAL EVOLUTION OF FMS-LIKE TYROSINE KINASE 3 (FLT3) GENE MUTATIONS DURING DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Vyas, P., et al.
Publicado: (2022)

Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies
por: Powers, Robert W., et al.
Publicado: (2010)

Fasudil attenuates soluble fms-like tyrosine kinase-1 (sFlt-1)-induced hypertension in pregnant mice through RhoA/ROCK pathway
por: Gu, Ying, et al.
Publicado: (2017)

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
por: Hannan, Natalie J., et al.
Publicado: (2017)

Circulating Maternal sFLT1 (Soluble fms-Like Tyrosine Kinase-1) Is Sufficient to Impair Spiral Arterial Remodeling in a Preeclampsia Mouse Model
por: Vogtmann, Rebekka, et al.
Publicado: (2021)

FMS-Like Tyrosine Kinase 3 Ligand Treatment Does Not Ameliorate Experimental Rapidly Progressive Glomerulonephritis
por: Ghali, Joanna R., et al.
Publicado: (2015)

Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3
por: Zeyn, Yanira, et al.
Publicado: (2023)

Closing Symposium of the DFG Research Unit FOR 1066
por: Radespiel, Rolf, et al.
Publicado: (2016)

Neurotrophin-3 and FLT3 Tyrosine Kinase Receptor in Perinatal Life
por: Malamitsi-Puchner, Ariadne, et al.
Publicado: (2005)

Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy
por: Gurnadi, Jeffry Iman, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5gb8sbb5n85cbv10gd0bupo747